Olema Oncology Set to Engage Investors at Key Conferences
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), is a pioneering clinical-stage biopharmaceutical company recognized for its commitment to developing groundbreaking therapies for breast cancer. With a focus on innovation and transformative care, Olema is gearing up for significant engagement as it participates in several upcoming investor conferences.
Upcoming Conference Details
In an effort to maintain transparency and build relationships with investors, Olema’s management team is scheduled to participate in a series of prominent conferences:
Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET)
Format: Fireside Chat
7th Annual Evercore HealthCONx Conference
Date: Tuesday, December 3, 2024, at 2:10 p.m. ET
Format: Fireside Chat
Citi’s 2024 Global Healthcare Conference
Date: Tuesday, December 3, 2024, at 3:15 p.m. ET
Format: Panel Discussion
Access to Live Webcasts
For those unable to attend in person, Olema will offer live webcasts of all presentations. These will be accessible through the News & Events section on Olema’s investor relations website. The webcasts will also be conveniently archived for at least 30 days, ensuring that all interested parties can access and review the information shared during the sessions.
About Olema Oncology
Olema Oncology stands at the forefront of biopharmaceutical innovation. The company is dedicated to enhancing the standard of care for women diagnosed with cancer. With a robust pipeline of novel therapies, Olema is leveraging its expertise in endocrine-driven cancers. The cornerstone of its portfolio is palazestrant (OP-1250), an innovative treatment that acts as a complete estrogen receptor antagonist and selective estrogen receptor degrader, currently undergoing a Phase 3 clinical trial known as OPERA-01. Furthermore, Olema is advancing the development of its potent KAT6 inhibitor, OP-3136, which underscores its commitment to groundbreaking cancer treatments.
Contact Information
For further inquiries, please reach out to:
Courtney O’Konek
Vice President, Corporate Communications
media@olema.com
Frequently Asked Questions
What is Olema Oncology known for?
Olema Oncology is recognized for developing targeted therapies aimed at improving outcomes for breast cancer patients.
What are the details of the upcoming investor conferences?
Olema will participate in the Jefferies London Healthcare Conference, the Evercore HealthCONx Conference, and Citi’s Global Healthcare Conference.
How can I watch the presentations?
Live webcasts of Olema's presentations will be available on their investor relations website and will be archived for 30 days.
What is palazestrant?
Palazestrant (OP-1250) is Olema’s lead product candidate, designed to act as a complete estrogen receptor antagonist and selective estrogen receptor degrader.
Who should I contact for more information about Olema?
For information, you can contact Courtney O’Konek at media@olema.com.